Related Experiment Video
Updated: Jan 21, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Targeting WDR5: A WINning Anti-Cancer Strategy?
Erin R Aho1, April M Weissmiller1, Stephen W Fesik2
1Department of Cell and Developmental Biology, School of Medicine, Vanderbilt University, Nashville, TN, USA.
None:
WDR5 is a component of multiple epigenetic regulatory complexes, including the mixed lineage leukemia (MLL)/SET complexes that deposit histone H3 lysine 4 methylation. Inhibitors of an arginine-binding cavity in WDR5, known as the WDR5-interaction (WIN) site, have been proposed to selectively kill MLL-rearranged malignancies via an epigenetic mechanism. We discovered potent WIN site inhibitors and found that they kill MLL cancer cells not through changes in histone methylation, but by displacing WDR5 from chromatin at protein synthesis genes, choking the translational capacity of these cells, and inducing death via a nucleolar stress response. The mechanism of action of WIN site inhibitors reveals new aspects of WDR5 function and forecasts broad therapeutic utility as anti-cancer agents.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Persuasion Strategies
Coping Strategies: Problem Focused
For example, consider a student who struggles to understand their...
Waterproofing and Anti-Bacterial Admixtures in Concrete
Waterproofing admixtures render concrete hydrophobic,...
Strategies of Self-Presentation II: Self-Verification
Coping Strategies: Emotion Focused

